Anebulo Pharmaceuticals(ANEB) - 2025 Q3 - Quarterly Results

FORM 8-K Filing Information This section provides essential details about Anebulo Pharmaceuticals, Inc. as the registrant and specifics of the Form 8-K filing Registrant Information This section identifies Anebulo Pharmaceuticals, Inc. as the registrant, detailing its state of incorporation, principal executive offices, and contact information - Registrant: Anebulo Pharmaceuticals, Inc., incorporated in Delaware[2] - Principal Executive Offices: 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734[2] - Registrant's Telephone Number: (512) 598-0931[3] Filing Details This subsection specifies the filing date of the Form 8-K, lists the company's registered securities, and confirms its status as an emerging growth company - Date of Report (Date of earliest event reported): May 13, 2025[2] Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $.0.001 par value per share | ANEB | The Nasdaq Stock Market LLC | - Anebulo Pharmaceuticals, Inc. is an emerging growth company[4] Item 2.02 Results of Operations and Financial Condition This section details the announcement of Anebulo Pharmaceuticals, Inc.'s financial results and business update for the quarter ended March 31, 2025 Financial Results Announcement Anebulo Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2025, and provided a business update through a press release issued on May 13, 2025, which is furnished as Exhibit 99.1 - Anebulo Pharmaceuticals, Inc. issued a press release on May 13, 2025[5] - The press release announced financial results for the quarter ended March 31, 2025, and provided a business update[5] - The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K[5] Item 9.01 Financial Statements and Exhibits This section provides a comprehensive list of all exhibits included in the Form 8-K filing, such as the press release and interactive data file Exhibits List This section lists the exhibits accompanying the Form 8-K filing, including the press release detailing financial results and the interactive data file cover page List of Exhibits | Exhibit Number | Description | | :------------- | :---------- | | 99.1 | Press Release dated May 13, 2025 | | 104 | Cover Page of Interactive Data File (embedded within the Inline XBRL document). | Signatures This section formally documents the authorization and signing of the Form 8-K report by the Chief Executive Officer Authorization and Signatory This section confirms the official signing of the Form 8-K report by Richard Anthony Cunningham, Chief Executive Officer of Anebulo Pharmaceuticals, Inc., on May 13, 2025 - The report was signed on behalf of Anebulo Pharmaceuticals, Inc. on May 13, 2025[11] - Signed by Richard Anthony Cunningham, Chief Executive Officer (Principal Executive Officer)[11]